期刊文献+

截短胰高血糖素样肽-1的构象研究 被引量:7

Conformation Research of Shorted Glucagon-like Peptide-1
下载PDF
导出
摘要 截短胰高血糖素样肽-1(sGLP-1)不仅具备刺激胰岛β细胞增生和降低血糖的功能,而且半衰期较长,具有非常好的新药开发前景.为了阐明sGLP-1的功能,本文运用圆二色光谱和荧光光谱探究了sGLP-1在不同条件下的构象,结果表明,sGLP-1在磷酸盐缓冲液中主要呈无规则构象,螺旋含量很低;在含十二烷基硫酸钠或三氟乙醇的磷酸盐缓冲液中主要呈螺旋构象.溶液pH值和温度变化对sGLP-1的构象影响显著.sGLP-1保留了结合并激活受体的关键残基,在受体的诱导下,在体内形成正确构象,从而结合并激活受体,发挥它的功能.研究结果表明,适当缩短GLP-1C端片段,能获得作用时间长、效力高的GLP-1类似物. Shorted glucagon-like peptide-1( sGLP-1) not only stimulate proliferation of pancreatic beta cells and decrease blood glucose,but also has a longer half-life. This make sGLP-1 has become a potential new drug in the future. In order to elucidate the function of sGLP-1,this study investigates the conformation of sGLP-1 in different conditions by circular dichroism spectrum and fluorescence spectrum. The conformations of sGLP-1 in phosphate buffer are mostly unordered structure and very low helix,and are mostly α-helix in phosphate buffer containing SDS or TFE. Temperature and pH values of solutions have great influences on the conformation of sGLP-1. sGLP-1 preserve the critical residues which are responsible for binding and activating receptor,Induced by receptor,sGLP-1 can form the correct conformation which can bind and activate receptor in vivo,then realize its function. The results show that appropriately truncate C-terminal segment of GLP-1, may obtain long-term and high efficiency GLP-1 analogues.
出处 《高等学校化学学报》 SCIE EI CAS CSCD 北大核心 2010年第7期1337-1341,共5页 Chemical Journal of Chinese Universities
基金 国家"十一五"计划科技重大专项"重大医药创制"项目(批准号:2009zx09102-53) 辽宁省高校创新团队项目(批准号:2006T002 2008T005 2009T003) 大连市科技计划项目(批准号:2008E11SF170)资助
关键词 截短胰高血糖素样肽-1 圆二色光谱 荧光光谱 构象 Shorted glucagon-like peptide-1 Circular dichroism spectrum Fluorescence spectrum Conformation
  • 相关文献

参考文献14

  • 1杨英,陈建华.胰高血糖素样肽1及其类似物的研究进展[J].中国医药生物技术,2008,3(2):140-142. 被引量:5
  • 2Mentlein R.,Gallwitz B.,Schmidt M.E..Eur.J.Biochem.[J],1993,214(3):829-835.
  • 3Li Y.,Shi C.H.,Lv Q.J.,Zhang H.M.,Li B.H.,Bian G.X.,Huang Q.S.,Zhang W.H.,Xue X.P.,Ren X.,Gao H.,Sun C.Y.,Wang J.,Zhang M.J..J.Pept.Sci.[J],2008,14(7):777-785.
  • 4Sreerema N.,Venyaminov S.Y.,Woody R.W..Protein Sci.[J],1999,8:370-380.
  • 5WANG Jing-Yan(王镜岩),ZHU Sheng-Geng(朱圣庚),XU Chang-Fa(徐长法).Biochemistry(生物化学)[M].Beijing:Hisher Education Press,2002
  • 6Kelly S.M.,Jess T.J.,Price N.C..Biochim.Biophys.Acta[J],2005,1751(2):119-139.
  • 7Parker J.C.,Andrews K.M.,Rescek D.M.,Massefski W.Jr.,Andrews G.C.,Contillo L.G.,Stevenson K.W.,Singleton D.H.,Suleske R.T..J.Pept.Res.[J],1998,52(5):398-409.
  • 8Neidigh J.W.,Fesinmeyer R.M.,Prickett K.S.,Andersen N.H..Biochemistry[J],2001,40(44):13188-13200.
  • 9Adelhorst K.,Hedegaard B.B.,Knudsen L.B.,Kirk O..J.Biol.Chem.[J],1994,269(9):6275-6278.
  • 10Murage E.N.,Schroeder J.C.,Beinborn M.,Ahn J.M..Bioorg.Med.Chem.[J],2008,16(23):10106-10112.

二级参考文献22

  • 1[1]Matthaei S,Stmnvoll M,Keilerer M,et al.Pathophysiology and phannacological treatment of insulin resistance.Endoer Rev,2000,21(6):585-618.
  • 2[3]Stonehouse AH,Holcombe JH,Kendall DM.Management of Type 2 diabetes:the role of incretin mimetics.Expert Opin Pharmacother,2006,7(15):2095-2105.
  • 3[4]Holst JJ,Gromada J.Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.Am J Physiol Endocrinol Metab,2004,287(2):E199-206.
  • 4[5]Deacon CF.Therapeutic strategies based on glucagon-like peptide 1.Diabetes,2004,535:2181-2189.
  • 5[6]Shechter Y,Tsubery H,Fridkin M.[2-Sulfo-9-fluorenylmethoxycarbonyl]3-exendin-4-a long-acting glucose-lowering predrug.Biochem Biophys Res Commun,2003,305(2):386-391.
  • 6[7]Vahl TP,Paty BW,Fuller BD,et al.Effects of GLP-1-(7-36)NH2,GLP-1-(7-37),and GLP-1-(9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.J Clin Endocrinol Metab,2003.88(4):1772-1779.
  • 7[8]Andersen NH,Brodsky Y,Neidigh JW,et al.Medium-dependence of the secondary structure of exendin-4 and glucagon-like-pepfide-1.Bioorg Mcd Chem,2002.10(1):79-85.
  • 8[9] Delgado E,Luque MA,Alcantara A,et al.Glucagon-like peptide-1 binding to rat skeletal muscle.Paptides,1995,16(2):225-229.
  • 9[10]Doyle ME,Theodorakls MJ,Holloway HW,et al.The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity.Regal Pept,2003,114(2/3):153-158.
  • 10[11]Lσpez de Maturana R,Willshaw A,Kantzsch A.et al.The isolated N-terminal domain of the giucagon-like peptide-1(GLP-1)receptor binds exendin peptides with much higher affinity than GLP-1.J Biol Chem,2003,278(12):10195-10200.

共引文献8

同被引文献45

引证文献7

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部